You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Metabolic conditions

Vutrisiran for treating hereditary transthyretin-related amyloidosis

  • Technology appraisal guidance
  • Reference number: TA868
  • Published:  15 February 2023
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Final draft guidance
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

History

Documents created during the development process.

Expected publication

  • Register of interests (PDF 259 KB)

    Published:
    15 February 2023
  • Equality Impact Assessment (Guidance development) (PDF 150 KB)

    Published:
    15 February 2023

Final draft guidance

  • Final draft guidance

  • Final appraisal document Final Draft Guidance (PDF 128 KB)

    Published:
    19 January 2023
  • Committee papers (PDF 3.77 MB)

    Published:
    19 January 2023

Invitation to participate

  • Final scope (PDF 156 KB)

    Published:
    14 September 2022
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 287 KB)

    Published:
    14 September 2022
  • Equality Impact Assessment (Guidance development) (PDF 127 KB)

    Published:
    14 September 2022
  • Final stakeholder list (PDF 168 KB)

    Published:
    14 September 2022

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

  • Draft matrix post referral (PDF 171 KB)

    Published:
    12 July 2022
  • Draft scope post referral (PDF 172 KB)

    Published:
    12 July 2022
Back to top